Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  testicular cancer
Stage/Subtype:  testicular cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-15 of 15 for your search:
Start Over
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 16
Sponsor: Other
Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, P30CA015704, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 to 69
Sponsor: Other
Protocol IDs: 2006LS032, UMN-MT2005-21, UMN-0608M90586, UMN-2006LS032, NCT00432094
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2008-0378, NCI-2011-01631, NCT00936936
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 03909, NCI-2009-01467, NCT01037790
Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 17811, NCT01557790
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IUCRO-0403, NCI-2013-00510, 1301010501, NCT01808534
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HP-00040420, GCC 0805, NCT01110226
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110148, 11-C-0148, NCT01341496
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02500, CDR0000700997, UPCI-10-115, 8808, P30CA047904, U01CA062490, U01CA062502, U01CA062505, U01CA069856, U01CA070095, U01CA099168, UM1CA186690, UM1CA186691, UM1CA186709, UM1CA186717, NCT01366144
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: RADIANT, NCI-2012-00588, NCT01625351
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-A-007-13, NCT01831089
Start Over